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CHAPTER I
INTRODUCTION
Among the first reports involving serum protein binding of drugs
is one covering work done by Moore and Roaf {1904).

They demonstrated

that several volatile compounds, such as ether and chloroform, had a
greater solubility in serum than in saline.
"substance interaction with proteins".

This was attributed to

Historically, a significant

advance in the era of modern drug-protein interaction was contributed
by

Davis (1942, 1943).

His research related the binding of sulfonamides

by plasma proteins to drug distribution in body fluids and indicated that
the bound portions were bacteriostatically inactive.

Within eight years,

several investigations describing serum-drug interaction of sulfonamide,
digitoxin, organic ions, penicillin, inorganic ions, and serum albumin
binding sites were published {Derouax, 1943; Farwaz and Farah, 1944; .
Klotz and Walker, 1947; Eagle, 1947; Scatchard, 1949, 1950; and Karush,

1949 1950) •
1

A classic review by Goldstein (1949) regarding drug and plasma
protein interactions focused upon the consequences of drug binding on
half-life, efficacy, distribution, and excretion of drugs.

His statement

that "the capacity of drug molecules to enter into specific combinations
with proteins poses for pharmacology its most :f'undamental task - to
comprehend the intimate nature of drug action in terms of these molecular
interactions" summarizes the importance of drug-plasma protein interactions.

1.

The Goldstein publication contributed to an increased awareness
and stimulated many researchers to investigate the protein drug binding
phenomenon.

Since 1949, many publications describing the binding of a

variety of drugs by plasma proteins have appeared.

Among the drug exam-

ined were anticoagulants, hypnotics, parasympatholytics, anti-infectives,
CNS stimulants, cardiovascular agents, etc. (Meyer and Guttman, 1968).
Weiner et al (1950) showed that several human protein fractions
had different affinities for binding dicumarol.

They found that beta and

gamma globulins bound 20% of the drug while alpha globulin and albumin
bound 50 and 99% respectively.

The low free plasma level, slow rate of

metabolism, slow rate of transformation, and low elimination rate of
dicumarol were attributed to extensive plasma protein binding.
Mark et al (1951) found that procaine amide was primarily
localized in various tissues, i.e. kidney, liver, spleen, etc.

To esti-

mate the extent of drug localization, it was necessary to determine the
amount of procaine amide bound by plasma proteins.

They found that 15%

of the drug was bound to non-diffusible constituents of plasma.
A report by Tonnesen (1956) stated that the slow elimination
of atropine in man might be due to interaction with plasma protein.

Em-

ploying ultrafiltration and ultracentrifugation techniques, he found that
a~er

the administration of a therapeutic dose of atropine, 50% was ab-

sorbed onto the plasma proteins.

Tonnesen concluded that the plasma

proteins served as a carrier by which atropine is transported to various
organs.

He also intimated that this binding may slow the elimination of

atropine in man .•

2.

In vivo results reported by Paul et al (1960) showed that 30%
of the non-ionized nitro:fUrans (nitro:fUrazone) were bound to plasma proteins, 50 - 90% of the anionic compounds (nitrofuran), while the cationic
drugs (furaltadone) were not bound to any appreciable extent.

The authors

failed to establish any connection between the protein binding of these
anti-infectives and their systemic effects.

The relative binding power

of the protein for the drug was not established nor was the possibility
of displacement within the drug-protein complex.

It is the consensus

that most drug-protein complexes are therapeutically inactive.
In 1960-1961, Anton, using equilibrium dialysis, confirmed that
in vitro protein bound sulfonamides were devoid of antibacterial activity
and that the binding activity varies greatly between mammalian species.
He also presented in vivo evidence that the distribution of sulfonamide
in the rat could be modified by competitive interference with its binding to plasma protein by other drugs, i.e. sulfinpyrazone, ethyl biscoumacetate, phenylbutazone, and iophenoxic acid.

The total number of

binding sites per molecule of human serum albumin for a sulfonamide was
determined by Clausen (1966).

Clausen also reported that other plasma

proteins (prealbumin, glycoproteins, and alpha 2-macroglobulin) possessed
secondary binding properties.
Eichman et al (1962) demonstrated that xanthine molecules
(caffeine, theopbylline, theobromine, etc.) formed drug-albumin complexes.
Their results indicated that the extent of the binding was partially
dependent upon the hydrogen ion concentration of the system, and the
acid strength ot the drug.

The inactivation of penicillins F, G, K, and X by human and
rabbit serum protein interaction was revealed by Eagle (1947).

Keen

(1965) found that the binding of these antibacterials showed considerable
variation between oxen, goats, horses, sheep, and pigs.

According to Keen,

these differences may be accounted for by the average plasma concentrations of albumin, differences in affinity for the drug molecule, and
ionic constitution of the different plasmas.

Temperature variation has

been characterized as another factor operant in the binding of penicillins,

I

I
I
!
I
~

!•

I
I

calcium, and anionic dyes.

In 1966, Keen reported that sulpb.a.methoxy-

pridazine, phenozmethyl penicillin, and phenol red could be displaced
from serum albumin by several anionic drugs

This displacement by agents

such as phenylbutazone and salicylate showed specificity.

Furthermore,

Keen determined the number of binding sites for phenoxymetbyl penicillin
and benzylpenicillin to bovine serum albumin.
In 1954, Goldbaum and Smith investigated the in vitro binding
characteristics of several barbituric acids to bovine serum albumin using
ultrafiltration.

Among the barbiturates studied were tbiopental, seconal,

pentobarbital, phenobarbital and barbital.

Their results showed that

gradually increasing the length of the substituted alkyl side chain from
two to six carbons increased the percent of the drug bound.

Hence, those

drugs having the shorter duration of pharmacological action bad the
greatest fraction bound.

Variation of pH, albumin concentration, and

drug concentrations produced:
1)

maximum drug-albumin complex at approximately pH 7.8;

4.

2)

an increase in bound drug with increased albumin concentration which plateaued near 4%;

3)

maximal and minimal·barbit}f'ate-albumin interaction at drug
concentrations of 25 x 10- and 1 x lo-3 M respectively.

They demonstrated that bound barbiturates could be partially displaced
from the drug-albumin complex by addition of other barbiturates and
dissimilar organic anions.

In vivo distribution and in vitro tissue

homogenate studies in the rabbit generally indicated the highest binding
of the barbiturates occurred in plasma
muscle

red cells.

liver heart

kidney lung brain

Finally, they estimated the number of binding sites

on bovine serum albumin for the barbiturates.
The work by Goldbaum and Smith provided evidence that barbiturate binding is "related to pH", drug concentration, and protein
availability.

Also, binding in vitro seems to be related in part to the

distribution of drugs in vivo.
Employing dosages approximately five to ten times that used
therapeutically, Lous (1954) examined the fate of three barbituric acids
in man.

Using three to four normal subjects per drug, his work indicated

that the highest plasma concentration of barbital (B), allypropymal (A),
and phenobarbital (P), occurred between four to eight hours, three to
nine hours, and twelve to eighteen hours, respectively.

A~er

adminis-

tration, the drugs were eliminated from plasma following an exponential
curve with total urine excretion for B, A, and P being 75-95%, 9-18%,
and 13-37% respectively.

The renal clearance was shown to be "independent

of plasma concentration but dependent upon urinary flow".

Lous found, by

ultrafiltration, experiments, that the percent of barbiturate bound to

5.

plasma was 95% (88-104) for barbital, 50% (33-71) for phenobarbital, and
60% (54-65) for allypropymal.
Also, in 1954, Taylor et al investigated the binding of thiopental by rabbit plasma in vivo and in vitro.

These data indicated that

the amount of drug bound in vitro closely resembled the amount bound in
vivo.

They also demonstrated that as the concentration of the thiopental

increased, the percentage of the thiopental bound decreased, resulting
in an enhancement of the sleeping time duration.
Waddell and Butler (1957) delved deeper into the distribution
and excretion of·phenobarbital in dog, mice and man, stressing the effects
of pH alteration upon the parameters studied.

In contrast to the results

obtained by Goldbaum and Smith, these authors presented in vitro phenobarbital binding data obtained by dialysis which indicated that the
percentage of the drug bound was only slightly affected by pH within the
normal physiological range found during acidosis and alkalosis.

Further-

more, they stated that "in a 4 gm. per 100 ml. solution of albumin, the
proportion of phenobarbital bound is almost independent of the phenobarbital concentration over the range of 20 to 100 mg. per liter".

They

also stated that binding by "human serum albumin did not differ significantly from bovine albumin".

In vivo experiments in dog, mice and man

revealed that after precipitation of acidosis, induced by

co2

inhalation,

and alkalosis, by hyperventilation or intravenous infusion of NaHC0 ,

3

plasma phenobarbital concentrations fell as blood pH decreased.

Experi-

ments measuring the effects of pH on phenobarbital -induced anesthesia
in mice indicated that alkalosis lightens phenobarbital anesthesia by

6.

decreasing drug concentration in the brain.

I
I

centration varies reciprocally with blood pH.

Thus, tissue/plasma conFinally, Waddell and

Butler presented data showing that the renal clearance of phenobarbital
was similar in man and dog; "The clearance of phenobarbital increases with
increasing urine flow in acid or alkaline urine, but at any given rate
of flow the clearance is much higher in alkaline than in acid urine."
The work cited here indicates that the pharmacological action
of many drugs is closely related to plasma protein binding and binding
site availability.

A number of these papers have reported that drug

binding to these proteins, whether albumin, globulins, glycoproteins, etc.,
is a function of pH, drug or protein concentration.

Duration of action

and metabolic fate are apparently influenced by these phenomena.

The

investigations involving phenobarbital by Goldman and Smith, Lous, Waddell
and Butler provide evidence showing that the drug is primarily bound by
serum albumin.

However, the effects of variation in drug concentration,

serum albumin concentration, and pH upon phenobarbital binding are in
some instances contradictory.

Also, binding site availability on human

serum albumin for phenobarbital has not as yet been established.
Inconsistencies in previous reports on phenobarbital binding
by serum albumin suggested the need for clarification in this area.

The

ratio of moles of drug bound per mole of albumin calculated by Goldbaum
and Smith was determined, using a value of 14.5 x 10-5M for their bovine
albumin concentration.

On recalculation, it appears that. this value

-5

should have actually been 14.7 x 10 M.

The larger value could have

resulted in a lower binding site estimation.

7.

Waddell and Butler stated

that the binding of phenobarbital to human serum albumin was affected
only to a slight degree by pH and that it was nearly independent of pH,
whereas Goldbaum and Smith state that phenobarbital binding to albumin
is related to pH.

Waddell and Butler reported that alkalosis induced in

mice increased the median anesthetic dose of phenobarbital.

They also

observed a decrease in phenobarbital plasma concentrations after inducing
acidosis in the dog.

These findings do not appear to be in concert with

their in vitro data; although Waddell and Butler indicated that they
performed some experiments involving the binding of phenobarbital to
hu.~an

serum albumin, they failed to present any data documenting their

findings.

The only direct data concerning the binding of phenobarbital

to human serum proteins were reported by Lous.

Lous estimated that in

vivo binding of the drug concentration found in human serum ranged
oe::;ween

a

si~gle

33-71%. However, the upper and lower values were obtained in
individual.

He did not determine the percent of protein in

tLe serum nor the blood pH of his samples.

Therefore, research involving

tl:cse problems entailed a confirmation and clarification of the characteristics exhibited by human serum albumin binding of phenobarbital sodium
when drug concentration, albumin concentration and pH were varied.

A

second phase included the determination of the number of binding sites
per molecule of albumin available to the drug.

These data were further

examined in regard to implications as to pharmacological effect in humans.

8.

CHAPTER II
MCl.TERIAI.S AND METHODS

In this study, experiments were designed to determine the
percentage of drug bound in vitro to human serum albumin (HSA) while
varying specific physical and chemical conditions.

However, all experi-

ments were conducted in an in vitro system approximating the normal in
situ HS.A environment as closely as possible.
The percentage of drug bound to HSA was determined by a modification of the equilibrium dialysis procedure of Anton (1960).

Equili-

brium dialysis confines the protein component within a bag formed from
a semi-permeable membrane.

This membrane allows unbound drug molecules

to freely diffuse into the solution surrounding the bag until equilibrium
is attained.

When unbound drug concentrations on both sides of the

membrane become equal, any drug increment in the protein compartment is
presumed to represent drug bound to protein.

The concentration and

percent of drug bound is determined as follows:
l)

Concentration of bound barbiturate

2)

%bound

barbiturate

= Concentration

of barbiturate
in the bag minus concentration
of barbiturate in dialysate

= Concentration of bound barbiturate x 100
Concentration of barbiturate in bag

The technique of equilibrium dialysis provided an uncomplicated method
for the study of protein binding.

It also allowed the convenience of an

overnight binding reaction and easily controlled temperatures.
Phenobarbital was assayed by the ultraviolet, spectrophotometric
method of Goldbaum (1952), and Goldbaum and Smith (1954).

9.

This procedure

>'··----------------------------.,
1:,,

•
~

~

combines precision, specificity, simplicity and sensitivity for the
measurement of microgram quantities of phenobarbital in saline, blood,
serum, and urine solutions.

To minimize experimental variance due to

pipetting errors, determination of data from standard curves, and other
extraneous variables, each experimental point was established on the basis
of three separate determinations.
in duplicate.

Ea.ch such determination was conducted

The average and standard error of the mean for each set of

phenobarbital values was calculated.

Protein concentrations were deter-

mined by the procedure of Gornall et al (1948).
Preliminary Experiments
Pilot experiments were conducted to assure that no interference
in binding or assay resulted from the cellulose dialysis tubing.

In

system one, 0.001 M phenobarbital Na in Sorensen's M/15 phosphate buf'fer
solution was placed in the dialysis tube (outer phase) while the dialysis
bag (inner phase) contained only the buf'fer.
phases were reversed.

In a second system, the

A buf'fer solution containing phenobarbital equal

in amount to that in the tube of system one was placed in the bag.

This

bag was then put into a dialysis tube containing only buf'fer solution.
A~er

16 hours dialysis, the buf'fer solutions in the tubes and bags of

both systems were analyzed for phenobarbital concentration.
Additional experiments estimated the minimal amount of time
necessary to attain system equilibrium.

The above procedure was repeated;

however, a three percent human serum albumin-buf'fer solution was placed
into the dialysis bags.

The dual systems were then dialyzed and assayed

after eight, twelve and sixteen hours.
10.

Minimal equilibrium time was

determined to be twelve hours.
Previous work by Goldbaum and Smith (1954) using ultrafiltration indicated that equilibrium values for barbiturate binding to bovine
0
albumin
· was unaff ect ed by t emperat ures ranging from 4° - 4o c.

ments were conducted at 37.5
above results.

0

c.

Experi-

and at room temperature, confirming the

Thus, for convenience, equilibrium dialyses were carried

out overnight through a period of 16 to 17 hours at room temperature.
A final set of preliminary experiments was conducted to confirm
the sensitivity of the assay and the percentage of phenobarbital Na
recovered.

The partition coefficient was determined as described by

Martin (1962) and employed to calculate the theoretical extraction and
percentage recovery of the drug.
RSA-Phenobarbital Binding Experiments
To ascertain a picture of HSA binding capacity and estimate'
the number of binding sites per molecule of albumin available to phenobarbital, the effect of drug concentration variation upon binding was
studied.

Concentrations ranging from that considered therapeutic to those

causing toxic reactions were investigated as follows:
-5
a) 12.5 x 10 M
e) 2 x lo-%1

I

b)

25 x l0- 5M

f)

4 x 10-;

c)

5 x l0- 4M.

g)

8 x lo-.\

d)

1 x 10-~

~~

T::c: 12.5 x 10-5M concentration was employed in all other experiments.

~
~

'l'his

~

i

•
.f,_.._,
!

concentration was assumed to be therapeutically equivalent to that

_____________________________________
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found in a nonnal 70 Kg. individual after administration of 150 mg. of
phenobarbital.
The normal range

of arterial blood

pH is 7.35 - 7.45, "any pH

below 7,35 or above 7.45 is generally defined acidosis and alkalosis
respectively", (Woodbury, 1965).

Many

acute and chronic disease states

clinically reveal an acid-base disturbance; therefore effects of pH
variation (6.6 - 7.8) upon binding were investigated.

A pH of 7.4 was

maintained in all other experiments.
The effects of varying concentrations of ,HSA (l to 6%) on
binding were also examined since there are clinical conditions in which
HSA variations from normal may occur.

For all other experiments, 3.o'fo

HSA was utilized.
Finally, the number of binding sites per molecule of human
serum albumin was estimated using the procedure described by Karush (1950).
System Components and Procedure
Unless specified, all solutions were made up using glass distilled water and employed at room temperature.

All compounds were weighed

on an analytical balance to the nearest 0.1 mg.
Dialysis Bags (Scientific Products #Dl615-2)
The dialysis bags were prepared from high purity, seamless,
re~~enerated
T~2

cellulose tubing (150 mm. in length and 28 mm. in width).

tubing was rinsed in glass distilled water, then washed for 15 minutes

in 900 C. glass distilled water, and finally rerinsed three times.

Washing

was done to eliminate any substances in or adhering to the cellulose
which might interfere with the analytical procedure.

12.

The tubing was

double knotted and trimmed at the distal end while the proximal portion
was tied securely to the end of a glass tube with blanched nylon thread.
The dialysis bags measured aJ?proximately 4.5 cm. from the end of the
glass tube to the :proximal end of the knot.

All bags were tested for

leaks by submerging the bags in water and blowing through the proximal
end of the glass tube, absence of bubbles being indicative of positive
closure.
Dialyzer Container
The dialyzer container consisted of a Pyrex (Corning ://9820)

25x100 mm. culture tube, Bacti-Capall (Scientific Products #T-1395-4)
and a one hole neoprene stopper (18x24 mm), through which was placed
Pyrex glass tubing (6 mm I .D. x 55 mm lg.).

The glass tube was fire

polished at one end and blunted to form a lip at the distal end.

The

proximal end of the glass tube then provided a porthole used to admit ·
the HSA into the dialysis bag while the distal lip provided a ledge to
which the bag was secured.
The Dialysis System Assembly Procedure (Figure l)
1.

A dialysis bag was tied to the glass tube of the neoprene

stopper and allowed to dry.
2.

Ten ml. of the appropriate phenobarbital Na/buffer solu-

tion concentration was pipetted into a culture tube and the base of the

I

tube inserted into a Bacti-cap which :provided a standu:p platform.

J

pi:oetted into the dialysis bag through the glass tube insertion port.

I
~

3.

Three ml. of the appropriate BSA/buffer concentration was

L,-------------------------------------...a
13.
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GLASS TUBE

4. Tne neoprene-dialysis bag assembly was then inserted into
the culture tube.

The glass tubing at the proximal end of the stopper

assembly was depressed until the HSA solution meniscus in the bag was
at a level equal to that of the culture tube phenobarbital Na solution.

5. A Bacti-cap was placed over the head of the entire assembly,
sealing in the contents.

The contents were dialyzed for 16 hours at room

temperature in a metabolic shaker at 80 strokes/min. using a 1-1/2 inch
stroke.
6.

At the end of this period, the contents of both the dialysis

bag and dialysis tube were analyzed for phenobarbital and protein concentration.
Human Serum Albu.min Solution (Calbiochem-Pentex Lot #17, 21, 23)
Electrophoretically pure crystalline human albumin was dissolved
in the appropriate M/15 buffer and refrigerated.

The HSA solutions were

used within 24 hours.
Phenobarbital Sodium (Mallinckrodt Chemical Works Lot

#DET)

The powder was dissolved in the phosphate buffer at the concentrations indicated on page ll.

The drug was solubilized in HSA

solution at a concentration of 0.001 M when determining system equilibrium.
Borate Buffer

74.554

@nS·

of KCl, reagent grade, and 61.844 gms. of boric

acid, reagent grade, diluted to one liter with water.
at room temperature for 24 hours and filtered.

15.

It was then stored

Sorensen's M/15 Phosphate Buf'fer (Hepler, 1960)
Sorensen's M/15 Phosphate Buf'fer was prepared by mixing the
appropriate quantities from stock solutions of:
l.

M/15 Potassium Acid Phosphate (KH Po ), 9.o8 gm. qs.
2 4
to l liter.

2.

M/15 Disodium Phosphate (Na HPo ), 9.47 gm. qs.
2
4
to 1 liter.

Sodium Hydroxide Solutions:
Sodium hydroxide solutions were prepared by diluting a comm.ercially available lON Analytical Reagent Grade Sodium Hydroxide solution
with glass distilled water.

1 N sodium hydroxide was used for washing

the chloroform extracting solvent.
the phenobarbital analysis.

Approximately 0.36 N was used in

The alkalinity of this solution was adjusted

to a pH of 10.4 by adding NaOH and borate buffer in a 2:1 ratio as
required.
Chloroform
Reagent grade chloroform was washed with 1 N sodium hydroxide
followed by two rinsings with glass distilled water.
solvent, 100 ml. of wash solution was used.

For every liter of

Only the volume necessary

for daily use was washed because the chloroform tends to decompose upon
standing.
Biuret Reagent (Harleco Lot #70101}
Tbe reagent was prepared in accordance with the procedure
described by Gornall et al.

The preparation consisted of a modified

alkaline copper'tartrate stabilized with potassium iodide.
16.

(For a detailed description of the procedures quoted, see the Appendix).

~

i

!i____________________________________________________
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CHAPTER III
RESULTS

Prior to commencing any experiments on the binding of phenoba ::'!Jital, we attempted to validate the analytical procedure for barbiturates as described in 1952 by Goldbaum (see Appendix).

The analytical

procedure involved an initial series of four extractions of phenobarbital
by

CHC1

3

from Sorensen's Buffer following addition of HCl.

this step, the pooled CHC1

Following

extract was re-extracted by NaOH.

Extraction

of phenobarbital in this second phase was virtually complete.

Using this

3

procedure, the phenobarbital recovery was found to be approximately

92-93'%· A theoretical recovery of 93.8% was calculated for phenobarbital.
Thus the theoretical and actual recovery of the barbiturate were comparable.
Employing a semi-log plot, Figure 2 illustrates the effects
of varied barbiturate concentrations upon the percentage of phenobarbital
bound by human serum albumin (HSA).

The amount of drug bound increased

while the percentage bound diminished as phenobarbital concentrations
increased.
tive, 12.5 x

Thus, at a concentration considered therapeutically effec-

io·5M, a high fraction of the drug was bound. The percent

of phenobarbital bound at 0.5 - 8 x 10-3 M, concentrations which would
appear to be toxic or lethal were significantly less bound than at
12.5 x 10

-5 M (Table 1).

18.
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TABLE I ,

Effect ot Varying Phenob&rb1tal Na Concentration
on Percentage ot Drug Bound b1 HSA at pH 7.4
Dru~

'lo Drug Bound

Concentration

p_o-5

M)

12.5
25.0
50.0
100.0
200.0

53.0
56.9
46.8
43.6
39.4

aoo.o

27.7 tl-58

400.0

* S.E.

Level of Significance

i:S.E.*

!0.58
to.54
t0.40
:o.66
to.70

0.01
0.001
0.001
0.001
0.001
0.001

37.4·t1;01

represents the standard error of the mean percentage of drug bound
The

changes in phenobarbita1 binding by human serum albumin

{HSA) binding due to pH alterations are depicted in Figure 3.

The

fraction of barbiturate bound declined as the hydrogen ion concentration
was increased.

The

sharpest decrease in binding occurred between pH 7.2

and 7 .4. According to Woodbury {1965), any pH above 7 .45 or below 7. 35 ·
indicates alkalosis and acidosis respectively.

Table II indicates tbat

the amount of drug bound was significantly less at pH's representing
acidosis than at normal physiological pH. Above pH 7.4, the percentage
of drug bound began to plateau.

However, at pH's

represen~ing

alkalosis,

a slight increase in phenobarbital binding occurred which became significant at pH 7 .8.

In the pH range investigated, the drug binding affinity

of the protein appeared to decrease as the pH was lowered.
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FIG.3
EFFECT OF pH VARIATION ON 3% HSA BINDING
OF 12.5 X 10-5 M PHENOBARBITAL Na
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TABLE II
Effect of pH A~teration on 3% HSA Binding
of 12.5 x io-5 M Phenobarbital Na

%Drug

Bound tS •E.

Level of Significance

53.0 ±0.76
Acidosis

7.2
7.0

38.6 t0.23
34.3 to.70

0.001
0.001

53.2 to.30
57.8 t0.24

N.S.
0.01

Alkalosis

7.6
7.8

Changes in the percentage of phenobarbital bound at various
concentrations of human serum albumin are portrayed in Figure 4.

A pro-

gressive increase in the portion of the drug bound occurred as the concentration of HSA was increased.

The sharpest rise in binding occurred

between two and three percent HSA after which percentage of drug bound
began to plateau.

Little difference in binding was observed between

three and four percent protein concentration.

When considering the moles

of drug bound per mole of albumin, the fraction of phenobarbital bound
was generally reduced as albumin concentrations increased (Table III).
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TABLE III
Effeot of Val'lins HS.A Concentration on Binding
of 12.5 x 10~.< M Phenobarbital at pH 7.4
.

%HSA

Concentration
1
2

3
4
6

%Drug Bound
-.t S.E.
2i.8
32.1
53.0
58.8
63.5

Moles Drug_
Bound x 10 5

Cone. HSA
Moles (10-5)

Fraction Drug
Bound/Mole HSA*

2.72
4.0l
6.62
7.35

14.5

0.19
0.14

+o.82
±0.74
:to.58
:t0.27
:to.59

7.94

29.0

0.15
0.13
0.09

43.5
58.0
86.8

*Assuming a molecular weight of 69,000 for HSA
The reduction in the fraction of phenobarbital bound per mole
of albumin can be attributed to a dilution of the drug in the albumin.
As the albumin concentration was increased, the number of binding sites
was increased while the barbiturate concentration remained constant.
To estimate the number of binding sites per molecule of
albumin, the moles of drug bound per mole of albumin (r) was determined
for several concentrations of the drug (see Appendix).

These ratios were

then related to the molar concentration of_ free drug present (c) by
making a lineal plot of r/c vs. r.

To minimize experimental error which

might have resulted due to techniques employed and to improve the accuracy
of binding site estimation, the percentages of drug bound used to calculate r were determined from Figure 2, as indicated in Table

rv.

The

semi-log plot allowed the determination of values from a straigh"l:; line.
The molecular weight for human serum albumin was assumed to be 69,000
(Phelps and Putnam, 1960).

The ionic strength of the phosphate buffer

at pH 7.4 was calculated at 0.17 arbitrary units (Martin, 1962).
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The

TABLE IV
Values Utilized for Characterization of
Phenobarbital Binding Sites
Initial
Drug Cone.

(10-5 M)

.

I\)

Vl

<f, Drug
Bound

Final Free
Drug Cone. (c)
(10-5 M)

Amount
Drug Bound

(10-5 M)

Moles Bound
Drug/mole
HSA (r)

r/c x 10

3

r/c x 10

12.5

53.7

5.8

6.7

0.15

2.59

1.44

25

50.3

12.4

12.6

0.29

2.33

1.35

50

46.9

26.6

23.4

0.54

2.03

1.15

100

43.2

56.8

43.2

0.99

1.74

l.o4

200

39.9

120.0

79.8

1.83

1.52

0.91

400

36.8

253

147.0

3.38

1.34

0.87

8oo

33.3

534

266.0

6.ll

1.14

0.85

3

(f)

concentration of human serum albumin was 43.5 x 10-5 M (3%).
Figure 5 presents the graphical estimation of phenobarbital
binding sites per molecule of albumin.

According to Karush (1950),

Scatchard (1949, 1950), and others, homogeneity of binding sites produces
a straight line plot.

When the line is extrapol.ated to the ordinate and

abscissa, the intercepts equal nK and n respectively (see Appendix).

If

the r/c vs. r relationship produces a curved line, two alternatives are
present.

The deviation from the straight line may be due to electro-

static factors or the binding sites are heterogeneous.
The plot of these data produced a curved line, Figure

5.

Therefore, we replotted the data using the electrostatic interaction
correction factor. The formula for electrostatic interaction is r/c (t)
2w(Zp+r)
·
where f equals e
(Keen, 1966). The factor (e) is the loglO of
the natural logarithm and (w) is the electrostatic parameter taken as
0.025, extrapolated from Tanford et al (1955).

According to Goldstein

(1949), the isoelectric point of albumin is 4.9 and carries a net negative charge at pH

7.4. Consequently, the charge on the protein (Zp) is

taken as -12 (McMenamy, 1968). A plot of r/ c (f) vs. r, Table 'IV,
produced a curved line, Figure 6.
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FIG.5
GRAPHICAL ESTIMATION OF PHENOBARBITAL BINDING SITES PER MOLECULE OF HSA
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Since we failed to demonstrate the presence of homogeneous

binding sites, an aesuiiwtion ot heteroseneous binding sites for phenobarbital was made (see Appendix).

Resolution of the binding curve

(Figure 5) indicated two components corresponding to sites, n1 and n •
2
Table V shows the values obtained for the albumin molecules binding sites
and their association constants for phenobarbital.

TABLE V
Values Detennined for the Number of
Phenobarbital Binding Sites (n) on the
Human Serum Albumin Molecule and Their
Association Constants (K) for Phenobarbital
Sites

.n

nK

K

Primary binding sites

0.95

950

1000

Secondary binding sites

14.05

1750

124

Total binding sites

15

2700

The relationship between free and bound drug concentration for
these groups of sites is expressed by an equation calculated by Karush (1950

1 + ~c

When the above values were substituted in the equation, the
broken line in Figure 5 was plotted.
tained with the experimental data.

This curve approximates that obExtrapolation of both curves estimates

the total number of binding sites to be approximately 15.

The data suggest

a primary group .of sites w1 th a greater affinity for phenobarbital and a

pt

L

T

~
I

'~

se.::onda.ry more numerous group with a lesser affinity as indicated by the
differences in the group association constants.
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DISCUSSION
The response of living systems to chemical stimuli such as drugs
is often widely varied between and within the species and frequently within an individual organism.

11

Most of the variation attending the use of

drugs, especially in therapeutics, lies in the wide ranges of physical,
biochemical, and pathological conditions that con:f'ront the drug when it
is administered to a living organism" (Condouris, 1965).

Plasma-protein

binding of drugs, particularly by serum albumin, demonstrates a notable
involvement in drug-response variation.

Drug binding by albumin can alter

therapeutic effectiveness, delay metabolic transformation or excretion,
and participate in drug interaction.

The slow release of a bound drug

may prolong drug blood levels, resulting in sustained

therap~

or the

bound complex may act as a protective carrier system by which a drug can
be transported to or removed from its site of action.

(Tonnesen, 1956;

Anton, 1960; Keen, 1966; Meyer and Guttman, 1968; Goldstein, 1949.)

The

binding of drugs by albumin is related to environmental pH, albumin concentration, and drug concentration (Goldstein, 1949; Goldbaum and Smith,

1954). Consequently, variations in the physical, biochemical, or pathological condition of an organism which change pH or albumin concentrations can influence drug binding and alter therapeutic effectiveness.
In 1954, Lous estimated the percentage of phenobarbital bound
in vivo by serum proteins.

He employed three normal human subjects and

repeated the experiment in one of the subjects to obtain four values.
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Each subject received 750 mg. of the barbiturate orally.
filtration, he found that
of 33 - 71% (50 :t8%).

s~~

Using ultra-

proteins bound phenobarbital at a level

Unfortunately, Lous did not report the blood pH

or serum protein content for any of the subjects.

Nevertheless, the

calculated average of 50'/o was fairly close to results we reported.
data indicated that approximately

Our

43 - 47% of a comparable in vitro con-

ccntration, between 5 x 10-4 and 1 x 10-3 M, was bound to albumin alone.
Th"-.:.s,

there appears to be some relationship between in vivo and in vitro

phl:~nobarbi tal

binding.

It has been reported that minor secondary binding

und sometimes primary binding occurs with other serum proteins such as
preaJ.bumin, alpha and gamma globulins, and glycoproteins (Goldstein, 1949;
Clausen, 1966; Meyer and Guttman, 1968).

However, album1n is considered

the primary binding entity for most drugs including phenobarbital.
Barbiturates in sedative or hy:pnotic doses act principally at
the level of the thalamus and the ascending reticular formation, interfering with impulse transmission to the cortex (Cutting, 1967).

These

drugs are capable of depressing many biological :f'unctions and are considered unspecific in their effects.

Although little is known about

their mechanism of action, barbiturates are only partially ionized at
biological pH's.

Available information indicates that the free acid

(undissociated) form is responsible for the depressant effects.
et al, 1959; Sharpless, 1966).

(Hardman

"Moreover, the drugs cross the cellular

membrane only in the form of undissociated molecules" (Maynert, 1965).
Examination of our pH data indicates a sharp increase in
phenobarbital bound as the pH is increased, 35% at pH 7.2 to 53% at 7.6.
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As the hydrogen ion content decreases, the fraction of the barbiturate
bound substantially increases and the amount of drug available to produce
an effect is diminished.
Waddell and Butler reported a

6~

difference in the fraction of

phenobarbital bound by albumin in vitro between pH 7.2 and 7.6.

They

stated that "binding is affected only to a small degree by pH", and that
"the binding is nearly independent of pH".

Nevertheless, their in vivo

experiments in mice indicate a 20% increase in the median anesthetic dose
of phenobarbital after NaHC0

3 induced al.kalosis. Waddell. and Butler also

observed a decrease in plasma phenobarbital concentration when acidosis
was induced by 002 in dogs.

Assuming that the drugs cross cellular mem-

branes only in the fonn of undissociated molecules and that the bound
fonn is inactive (Goldstein, 1949; Maynert, 1965), the in vivo and in
vitro· results and conclusions of Waddell. and Butler appear to be inconsistant.

On the other hand, our results and those of Goldbaum and Smith

correlate nicely with the in vivo data of Waddell. and Butler.

The in-

fonnation reported above indicates that phenobarbital binding as well
as drug response are apparently pH dependent.
The binding of an anionic drug molecule by albumin can be
ascribed to the availability of the free imidazole,f-amino, and guanido
groups of the basic amino acids - histadine, lysine, and arginine, respectively.
The dissociation constants for phenobarbital and the amino
acids are represented by their pKa values.
a weak acid, is. 7.4 (Martin, 1962).

The pKa for phenobarbital,

The pKa's for the imidazole group
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of histadine, the f -amino group of lysine, and the guanido group of
arginine are 5.6 - 7.0, 9.4 - 10.6, and ll.6 - 12.6 (White, Handler, and
Smith, 1964).

The acidic

and basic

dissociation constants may be cal.cu-

lated by substitution in the following equations:
pKa

= pH

+ log non-ionized acid
ionized acid

pKa = pH + log

ionized base
-------non-ionized base

(l)
(2)

Examination of the pKa, pH and the equation involved provides a basis for
determining the extent of drug or amino acid ionization.
As the hydrogen ion concentration in a solution containing
phenobarbital is decreased, the amount of the drug ionized is increased
(equation l).

Thus, the anionic form of the phenobarbital molecule be-

comes more available for binding as the pH is increased from 6.6 - 7.8.
In contrast, this alteration of pH results in a positive charge on the
free groups of the basic amino acids {equation 2).

The presence of

increasing amounts of the anionic and cationic charged molecules in the
solution provides for increases in the drug-protein binding.

Since the

imida.zole group las the lowest pKa, it is likely that this is the group
primarily responsible for the binding of phenobarbital to human serum
albumin.
Like Goldbaum and Smith, many researchers have reported a
reversal of the fraction of drug bound above pH 7.8.

This decrease in

association above pH 7.8 is rationalized by Eichman et al (1962).
assume:

1) the occurrence of a specific interaction between a
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They

"proteinated site" on the albumin and the drug, or 2) a change in the
configuration of the binding sites "resulting from the neutralization of
a proteinated group on the protein".

Either or both may result in a

disruption of the drug-protein complex.

They point out that

~--a.mine

groups

dissociate in the pH range where binding reversal transpires, and tbat
"it is quite possible tbat neutralization of such groups is related to
the marked decrease in the interaction".
Our pH data and that of Goldbaum and Smith suggest tbat change
in the blood hydrogen ion content may affect the dosage at which phenobarbital and other barbiturates a.re therapeutically effective.

Binding

differences over a nonnal pH of 7.35 - 7.45 amount to approximately 4.5~
in vitro.

Disease states evoking disturbances in acid-base metabolism

leading to acidosis or alkalosis such as renal disorders, respiratory
disorders (tuberculosis, emphysema), types of adrenocorticism, or diabetes
mellitus, provoke significant pH alterations.

Although barbiturates may

often be contraindicated in these conditions, sedative and hypnotic doses
o:f' phenobarbital are administered to relieve insomnia and anxiety prior
to knowledge of their etiology.

Undissociated phenobarbital availability

appears to be a :factor in drug dose-response relationship.

Consequently,

aey disease states evoking pH changes would contribute to the problems
of drug dosage variability between and within patients.
The concentration o:f' albumin in serum between individuals is
highly varied.

Altman and Dittmer (1961), using reports published in the

1950' s, compiled a table showing a range of 2. 0 - 4. 5 g/100 ml.
sources suggest .an average concentration of 3.5 g/100 ml.
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Other

The consensus

places the average HSA concentration between three and four percent.

Little

difference in binding was observed (5 percent) between HSA concentrations
of 3 to 4 percent. A sharp decrease in the amount of drug bound was observed below 3 percent.
Smith.

Our work supports the findings of Goldbaum and

We all observed that 3 percent albumin bound approximately 43~

of the phenobarbital.

Differences between human serum albumin and bovine

serum albumin seem small and many drugs are bound to approximately the
same extent by both.

"In general, however, the complete unpredictability

of species differences and variation of relative binding power with
different drugs dictate caution in transferring interaction data between
species 11 (Goldstein, 1949; Tanford, 1955).

The results obtained appear

to indicate that HSA expresses its greatest influence upon the drug binding
at concentrations below 3 percent.
above

More subtle binding changes occur

4 percent. Conditions such as dehydration, renal disease, liver.

disease, and malnutrition, lead to HSA alterations.

Changes in albumin

concentration could be a participating factor in the regulation of phenobarbital dose-response by controlling the number of albumin molecules with
available binding sites.
Given a specific pH and HSA concentration, increasing phenobarbital concentrations provide a larger quantity of undissociated drug.
Consequently, toxicity results when a sufficient amount of the free acid
becomes available.

As the phenobarbital concentration increased, the

moles of drug bound per mole HSA ratio increased proportionately until
concentrations approximating toxic levels were attained.

At 100 x 10-5M,

this proportionality began to decrease. Although the percentage of drug
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bound at 8oo x l0- 5 M was low, the ratio indicates that approximately 40
times more drug was bound per molecule of BSA at this concentration than
at 12.5 x l0- 5 M (Table IV).·.. It would appear that the presence of phenobarbital may affect the affinity of the protein for the barbiturate.

The

decrease in proportionality may be attributed to binding site saturation
and/or a distortion of binding site configuration due to saturation.
When the environment of the albumin is altered, the response
of the' organism to phenobarbital can become quickly magnified.

Higher

concentrations of the drug not only provide more of the free acid fonn
but can cause depressed respiration leading to respiratory acidosis.

This

decrease in pH would result in a further magnification of the phenobarbital.
response.
Karush together With Goldbaum and Smith have stressed the importance of the number of binding sites per molecule of protein (n) in.
the drug-protein complex.

It was estimated from these results that human

serum albumin has a totai n of 15 for phenobarbital.
class of sites (n1

= 0.95)

There was a primary

and a more numerous secondary class (~= 14.05).

Goldbaum and Smith determined that bovine serum albumin (BSA) had 22 n.
The BSA sites consisted of a primary group with a smaller n1 (0.3) and
a larger secondary n2 (21.7).

Moreover, the~ association constant was

extremely high when compared with ours (287,000. vs. 1000). A comparison
between secondary association constants showed some agreement, 90 vs. 124.
Thus, BSA not only had more binding sites per molecule albumin than BSA
but the overall affinity for binding phenobarbital was stronger.
Given .constant physiological and biochemical conditions, it is
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tempting to attribute species differences in phenobarbital response to
the number and character of the binding sites found on serum albumin.
However, binding data such as"reported in this disse~ation have not become available for albumin of species other than bovine.
In conclusion, a comparison between these data and results obtained by Goldbaum and Smith, Taylor et al (1954), Waddell and Butler,
and Lous, provides a correlation between in vitro and in vivo binding of
phenobarbital by serum albumin.

The drug-protein complex is a :f'unction

of the number of binding sites available.

But the extent of phenobarbital

binding is dependent upon pH and related to the serum albumin concentration and the drug concentration. Any disease states altering these parameters alter phenobarbital binding by HSA and may produce variations in
the drug dose-response relationship.
SUMMARY

1.

Phenobarbital binding is related to hydrogen ion concentration, being
maximal at about pH 7 .8.

The percent of drug bound sharply decreased

below pH 7.35.
2.

At a given concentration of phenobarbital, the fraction of drug bound
approaches maximum with increasing albumin concentration.

However,

the fraction of bound drug per mole HSA diminishes.

3. As the phenobarbital concentration increases, the fraction bound
decreases; however, more drug is bound per molecule of HSA.

4. A total number of 15 binding sites per molecule of HSA is estimated
for phenobarbital.

Two classes of sites were determined, a primary

eroup with high affinity and a secondary group with much less af':f'inity.
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5 • The percentage of phenoba.rbi tal bound by HSA in vitro was found to be
similar to previously published results obtained in vivo.

6. Alterations in physical, '~d chemical conditions, are related
binding of phenobarbital by HSA.

to the

In the opinion of this author,

alterations in these para.meters which ca.use changes in phenobarbital
binding can contribute to drug dose-response variations.
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CHAPTER V

APPENDIX
Phenobarbital Detennination:

Method of Goldbaum (1952)

This procedure has its basis in the fact that barbiturates have
one absorption band in strong alkali and another in solutions between 10.2
a:nC:

10.6 showing characteristics of two different resonance forms.

The

optical density difference between the two forms is greatest at 260 mu
"for alkaline solutions containing 2-30 mcg. of barbiturates/ml." These
differences follow Beers Law and are used to quantitiatively measure
pb~nobarbital

concentrations.

From a survey of the literature, it is

concluded that ultraviolet, spectrophotometric techniques are the most
sensitive for quantitative and qualitative identification of barbiturates •
..

The Goldbaum method provides a highly specific identification for barbiturates.

It also allows for differentiation between many of the barbi•

turates.
Reagents:

Borate buffer, 0.36 N sodium hydroxide, washed
chloroform, glass distilled water, and the
appropriate M/15 Sorensen's pH buffer.

Decant solutions from dialysis bag and tube into separate test
tubes.

Pipette a portion of each solution into separate volumetric flasks

and dilute to a concentration approximating 50 mcg./ml.

Place 5 ml. of

each diluted solution into separate, dry, 125 ml. polypropylene-stoppered
separatory funnels.

Acidify each solution with 3 drops of 6 N HCl.

The

pH should be between 1-2 using pH paper.
Add 15 ml. of chloroform to each funnel and shake vigorously
for 1 minute.

Drain the chloroform layer through a #1 Whatman filter paper
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containing approximately 10 gms. of Na2so into a dry separator:y funnel.
4
Repeat the extraction with aliquots of 15, 10 and 10 ml. of chlorofom •

..

Collect the filtered extracts in the second separator:y tunnei.

Finally',

rinse the filter with 10 ml. of chloroform.
Pipette 10 ml. of 0.36 N NaOH into the separator:y funnel containing the chloroform extracts and shake for 10 min. on a mechanical
shaker to extract the phenobarbita.J. into the NaOH layer.

After shaking,

drain and discard the chloroform layer and collect the aqueous alkaline
layer in a 12 ml. centrifuge tube.

Centrifuge for 2- 3 min. at 2000 rpm

to precipitate any chloroform.
Transfer approximately 3 ml. of the alkaline extract to matched
quartz cuvette and determine the optical density at 260 mu. in a Beckman
DU spectrophotometer against a water blank.

Pipette 4 ml. of the alkaline

extract into a tube containing 2 ml. of the Borate buffer.

Pour 3 ml. •. of

this solution into a clean cuvette and determine the optical density at
260 mu.

The appropriate Sorensen's buffer is carried through the same
procedure as a reagent blank.
The optical density of the alkaline-borate solution is corrected
for dilution by multiplying by 1.5, and then it is subtracted from the
optical density of the alkaline extract.

The difference is employed to

determine the phenobarbital concentration after appropriate dilution
corrections.
A standard curve is plotted of the optical density differences
obtained from

s~veral

known concentrations of phenobarbital Na extracted

using the above procedure.

The experimental phenobarbital concentrations

were determined from the standard. curve.
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Protein Determination
The method described by Gornall et al (1948) is based on the
formation of a violet color ~hen copper sulfate in a strongly alkaline
solution reacts with proteins or polypeptides having peptide or amide
linkages.
Reagents:

Biuret reagent of GornaJ.l et al contains l.5 gm.

cupric sulfate (CuS04.5H20), 6.o gm. potassium tartrate (NaKC4H o6 .4~0)
4
dissolved in approximately 500 ml. of distilled water to which is added
300 ml. of 10% naOH. qs. to 1 liter.
The dialysate, the HSA solutions, and the appropriate Sorensen's
Buffer (reagent blank) are diluted 1:10 with water and one ml. of each is
pipetted into separate test tubes.

4 ml. of the reagent is pipetted into

each tube and the mixture allowed to stand for 30 minutes at room temperature.

The optical densities of the solutions were determined in a Beckman

DU with one cm. cells at 540 mu using a blank of glass distilled water.
Human serum albumin standards were used as controls and various
concentrations were employed to plot standard curves from which protein
concentrations were determined.

Partition Coefficient (Pc) and Per Cent Theoretical Extraction
The Pc of phenobarbital Na and its extraction was determined
using the method described by,Martin, (1962).
The Pc is based upon the distribution of a solute between immiscible solvents.

When a substance is added to the immiscible solvents in

a quantity insufficient to saturate the solutions, it becomes distributed
and c2 are the equilibrium concentrations of the substance in solvent 1 and solvent 2 , then
the equilibri~ constant (k) =
between the two solvents in a definite ratio.

Pc

=

concentration of Phenobarbital
concentration of Phenobarbital

If

c1

in Sorensen's Buffer (C1)
in CHCl3 (c2)

Once the Pc is determined, it is employed in the following formulas to
calculate the theoretical extraction and percent recovery.

,
2.

x mg./cc.

theoretically extracted "" wl + w2

Percent theoretical recovery

=

X
~
concentration in original solvent x lOO~

Where W = theoretical number of milligrams of solute extracted repeatedly
from v1 ml. of one solvent (Sorensen's buffer) with successive portions of
v2 ml. of a second immiscible solvent (CHc1 ), w1 "" amount of solute left
3
in original solvent after the first extraction, and w2

= the

amount of

solvent remaining in the original solvent after repeating the extraction
procedure using v2 number of ml. of solvent.
The Pc procedure was as follows:
l.

Dilute 500 mg. of phenobarbital Na to 100 ml. with Sorensen's pH 7. 4
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buf'fer ( c1 ) • Pipette 20 ml. of this solution into a separatory funnel and
add 20 ml. washed CHC1
1 minute.

3

(pipette).

Add 3 drops ot 6 N HCl and shake for

Pipette 10 ml. of"the CHC1 layer into a tared beaker.

3

Evapor-

ate CHC1 3 to dryness and weigh beaker to determine the phenobarbital
residue gravimetrically (c2 ).
2.

a)

buf'fer.

Dilute 500 mg. of phenobarbital Na to 100 ml. w1 th Sorensen's
Pipette 40 ml. of this solution into a separatory funnel and

add 40 ml. CHC1

3

(pipette). Add 3 drops of 6 N HCl and shake one minute.

Remove 10 ml. CHc1 and repeat step #1, me.king the dilution correction.

3

This serves as a control CHc1

3

extraction of phenobarbital and confirms

step #l.
b)

Using a pipette, remove 20 ml. of the CHc1

3

layer remaining in

the separatory funnel from (a) and place into a second separatory funnel.
Pipette 20 ml. 0.36 N NaOH into the funnel.
mechanical shaker tor 10 minutes.

Shake the contents on a

Pipette 10 ml. of the CHc1 layer into
3

a tared beaker and repeat (a).
c)

Subtract (b) from (a) to determine the amount of phenobarbital

extracted by NaOH from CHc1 •
3
The partition coefficient for
Concentration of Phenobarbital in Sorensen's Buf'fer
Concentration of Phenobarbital in CHC1

3

was calculated to be l.226.

Estimation of Protein Binding Sites - Method of Karush (1950)
The mathematical analysis of binding data has been thorougbl.y

discussed by Scatchard. (1949), Scatchard et al (1950), Karush and
Sonenberg (1949)~ Karush (1950), Eichman et al (1962), and Keen (1966).
These investigators estimated the number of binding sites per molecule
of albumin for various drugs as follows:
1.

The moles of drug bound per mole of albumin (r) is deter-

mined for several concentrations of the drug.
2.

Then (r) is related to the molar concentration of the free

drug present (c) by preparing a linear plot of r/c vs. r values.

3. The curve resulting from the r/c vs. r relationship is
extrapolated to the ordinate and the abscissa.

The authors state that

the values at the intercept points on the ordinate and abscissa equal nK
and n respectively.

"K" is equal to the association constant and "n"

equals the number of binding sites.
According to these authors, a plot of the r/c vs. r values
produces a straight line when a single, homogeneous group of sites is
responsible for drug binding.

Scatchard. points out that the relationship

between the concentrations of bound and free drug is expressed by the
formula:
r/c = nK - nr
Should the r/c versus r plot produce a curved line, the deviation from a
straight line may be due to electrostatic interaction.

Electrostatic

interaction is attributed to the repulsion of approaching drug ions by
those already bound.

An electrostatic correction factor may be applied

46.

by plotting r/c (f) versus r, when f equals e2w(Zp+r).

"e" is the natural

log, "w" the Debye-Huckle parameter, and Zp is the net charge on the protein.

"

The relationship between the concentrations of bound and free drugs

are represented by the formula (Keen, 1966):
r/c (f)

= nK

- rK

If a curved plot persists a~er r/c correction for electrostatic interaction, heterogeneity of binding sites is assumed.

The experi-

mental plot is extrapolated to graphically estimate the total number of
binding sites, the number of binding site groups, and their affinity for
the agent being studied.

"Assuming that there are n binding sites.of two

types, n and n2 with association constants K1 and

!<2

1

and A is the limiting

value of r/c as c approaches zero", the equation for the relationship
between free and bound drug concentrations is:
r/c =
where n

= n1

+ ~, and line r/ c

and Smith, 1954).

n1 IS_

n2 ~

+ _ __
l + IS_ c
1 + K c
2

= n1K1

+ ~ = A (Karush,

1950; Goldbaum

The association constant (K) for each class of sites

is determined by dividing the class nK value by its n value.
The graphically determined n and K values are substituted into
the appropriate equation to solve for r/c.
r values are plotted.

The calculated r/c ratio vs.

This plot should produce a curve similar to that

originally drawn and extrapolated (Keen, 1966) •
The estimation of the number and character of phenobarbital
binding sites per molecule of human serum albumin was determined in the
manner described.
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